Company intelligence / Profile preview

Quantoom Biosciences

Nivelles, Brabant Wallon, Belgiumquantoom.com ↗

Ownership: Private
Development stage: Commercial

Overview

Quantoom’s platforms have demonstrated performance in numerous pre-clinical studies and target-species evaluations. The company focuses on providing scalable mRNA production systems validated at the preclinical level for use by partners globally. No direct clinical trial results are reported as the company itself does not sponsor therapeutic programs.

Therapeutic areas: OncologyInfectious Diseases
Modalities: mRNAself-amplifying RNA (saRNA)nucleic acid therapeutics
Industry: Non-Drug Biotech

Partnerships

eTheRNA (advanced small-footprint RNA production)DNA Script & EVA Pharma (Africa-focused end-to-end mRNA production)Oswaldo Cruz Foundation/FIOCRUZ & Univercells (Brazilian vaccine/drug manufacturing)Exothera (process development collaboration)

Beyond the preview

Go deeper on Quantoom Biosciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Quantoom Biosciences.

Explore the full profile